Omeros OMER
NASDAQ OMER
$18.95 -0.16 (-0.84%)
At close: Sep 4, 2026 · 4:00 PM EDT

Omeros (OMER) Other Accumulated Expenses (2011 - 2026)

Omeros (OMER) posted Other Accumulated Expenses of $617000.0 for Q1 2026, up 63.23% sequentially from $378000.0 in Q4 2025, and up 10.18% YoY from $560000.0 in Q1 2025.

Analysis

Omeros (OMER) Other Accumulated Expenses (2011 - 2026) Analysis & Trends

Omeros has reported Other Accumulated Expenses for 12 years, with the latest figure at $617000.0 in Q1 2026.

  • Quarterly Other Accumulated Expenses rose 10.18% year-over-year to $617000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $617000.0 (up 10.18% YoY) and the FY2025 annual result came in at $378000.0, up 92.86% from the prior year.
  • Other Accumulated Expenses rose to $617000.0 in Q1 2026 per OMER's latest filing, from $378000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $30.6 million in Q4 2022 and troughed at $196000.0 in Q4 2024.
  • A 5-year average of $7.0 million and a median of $674000.0 in 2022 frame the typical range for Other Accumulated Expenses.
  • The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses sank 98.97% in 2023, then surged 4158.17% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $30.6 million in 2022, then tumbled by 98.97% to $316000.0 in 2023, then plunged by 37.97% to $196000.0 in 2024, then surged by 92.86% to $378000.0 in 2025, then jumped by 63.23% to $617000.0 in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods registered $617000.0, $378000.0, and $272000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Omeros 1.38 Bn 1.38 Bn 27.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 328,000.00
Mar 31, 2026 617,000.00
Dec 31, 2025 378,000.00
Sep 30, 2025 272,000.00
Jun 30, 2025 335,000.00
Mar 31, 2025 560,000.00
Dec 31, 2024 196,000.00
Sep 30, 2024 23.25 Mn
Jun 30, 2024 27.97 Mn
Mar 31, 2024 28.40 Mn
Dec 31, 2023 316,000.00
Sep 30, 2023 858,000.00
Jun 30, 2023 847,000.00
Mar 31, 2023 667,000.00
Dec 31, 2022 30.55 Mn
Sep 30, 2022 674,000.00
Jun 30, 2022 1.40 Mn
Mar 31, 2022 1.41 Mn
Dec 31, 2021 1.68 Mn
Sep 30, 2021 746,000.00